Received Feb 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | EN6200 | SYR / AR |
Prior to receiving the second dose of the Pfizer COVID-19 vaccination, Patient (born 1933) was in excellent health. She lived independently in a senior living apartment, walked daily, drove, traveled, and participated in regular social activities with friends and famiy. She managed her own finances and prepared tax returns for family members. Her only chronic medical condition was mild hypertension treated with metoprolol 50 mg daily. Patient received the first dose of the Pfizer COVID-19 vaccine on 1/30/2021. She received the second dose on 2/20/2021. Following the second dose, she developed severe, persistent fatigue beginning immediately afterward, with a marked decrease in activity level. Over subsequent months in 2021, she developed generalized weakness, mild dizziness, progressive lower extremity edema, and functional decline. Despite evaluation and laboratory testing in mid-2021 showing no significant abnormalities, her symptoms persisted. Physical therapy was prescribed in September 2021 for suspected deconditioning. Over the following months, she experienced multiple falls, became dependent on a walker for ambulation, developed a pressure sore requiring nursing care, and demonstrated a significant decline from her prior independent baseline. On 3/30/2022, she was taken to the ER by ambulance, was hospitalized and diagnosed with an acute stroke (hospitalized 3/30?4/4/2022), followed by skilled nursing rehabilitation from 4/4?5/10/2022. Due to ongoing deficits, she was no longer able to live independently and was required to move to assisted living on 5/10/2022. She became wheelchair dependent. Neurologist visits and tests revealed ?moderate atrophy? in brain, but ?nothing concerning?, according to the nuerologist. In December, the neurologist determined that she displayed some Parkinsonian-like movements and prescribed a one-half dose of carbadopa/levodopa. On 1/13/2023, she was taken to ER by ambulance, and hospitalized for a pulmonary embolism and underwent a thrombectomy to remove blood clots from the lungs (hospitalized 1/13?1/19/2023). She continued having trouble with balance and movement and her posture deteriorated, In July, her Parkinson?s medication was increased. While her lab results were overall good, her GP diagnosed her with dementia. In January 2024, she was hospitalized from 1/16?1/22/2024 for acute psychosis and unresponsiveness, followed by skilled nursing rehabilitation from 1/22?2/16/2024. She was taken off the Parkinson?s medication. She was again hospitalized from 3/5?3/16/2024 for angioedema, followed by rehabilitation from 3/16?4/1/2024. Due to continued decline, she was moved to an adult care home for Level IV care (full-assistance high-level support). At this time, Patient had progressive loss of speech, difficulty swallowing requiring thickened liquids, loss of continence and became completely bed-ridden. On 5/10/2024, she was transported by ambulance to the emergency department with dystonia and sepsis and was returned home and placed on hospice care. Patient died on 6/5/2024. The cause of death listed on the death certificate was Parkinson?s disease. However, she was never formally diagnosed with Parkinson?s disease. A neurologist had previously noted parkinsonian-like symptoms and trialed a low-dose carbidopa/levodopa, which was later discontinued following an episode of psychosis.
None
Mild hypertension (well controlled with Metoprolol 50 mg) only
Metoprolol 50mg daily, Fish Oil
None
Numerous tests and lab work done over the course of Patient's three years of declining health: Laboratory tests in 2021 reportedly normal. Stroke confirmed March 2022. Pulmonary embolism confirmed January 2023 (treated with thrombectomy). Neurology evaluations noted brain atrophy and parkinsonian-like symptoms without formal Parkinson?s diagnosis